Hypertrophic Cardiomyopathy Market Infographic
Hypertrophic Cardiomyopathy Market

Hypertrophic Cardiomyopathy (HCM) is a heterogeneous myocardial disease, most often caused by autosomal dominant sarcomeric gene mutations, representing the most common monogenic cardiomyopathy in humans. Family history is one of the major risk factors for the occurrence of Hypertrophic Cardiomyopathy. Hypertrophic Cardiomyopathy affects at least 1 in 500 adults and is the most common genetic heart disease in the U.S. It is observed that Males are more affected than females. Hypertrophic Cardiomyopathy symptoms include chest pain, fainting, heart murmur, palpitations, and shortness of breath.


Hypertrophic Cardiomyopathy Epidemiology Segmentation in 7MM from 2018 to 2030


  • Prevalent Cases of Hypertrophic Cardiomyopathy
  • Diagnosed Cases of Hypertrophic Cardiomyopathy
  • Type-Specific Cases of Hypertrophic Cardiomyopathy
  • Gender-Specific Cases of Hypertrophic Cardiomyopathy


Hypertrophic Cardiomyopathy Epidemiology Insights Observed in 2020


  • The diagnosed cases of Hypertrophic Cardiomyopathy in the US were found to be 109,215.
  • Among all the cases in the US, 72,810 cases were found to be of Obstructive HCM (HOCM), while 36,405 cases were of Non-obstructive HCM (HNCM).
  • Among the EU countries, Germany accounted for 29,453 HCM diagnosed cases, while Spain had 17,335 diagnosed cases. 
  • As per DelveInsight analysts, Japan had 3,997 diagnosed Hypertrophic Cardiomyopathy cases.


Hypertrophic Cardiomyopathy Market Insight


The Hypertrophic Cardiomyopathy Therapeutics market in the 7MM was found to be USD 301.3 million in 2020.


Hypertrophic Cardiomyopathy Market Drivers


  • Genetic diagnosis
  • Robust pipeline
  • Evolution of surgical techniques
  • Increasing the number of cases


Hypertrophic Cardiomyopathy Market Barriers


  • Underdiagnosis
  • Missing causal genes
  • Knowledge gaps


Hypertrophic Cardiomyopathy Emerging Therapies


The emerging drugs in the Hypertrophic Cardiomyopathy market are


  • Mavacamten
  • CK-274
  • LCZ696, and many more


Hypertrophic Cardiomyopathy Prominent Players


The key companies in the Hypertrophic Cardiomyopathy market are


  • Bristol Myers Squibb
  • Cytokinetics
  • Novartis, and several others.